Monday, November 21, 2022 8:12:11 AM
7:29 am ET November 21, 2022 (Dow Jones) Print
By Angela Palumbo
Merck announced Monday it would buy biopharmaceutical company Imago BioSciences in a deal valued at $1.35 billion.
Pharmaceuticals giant Merck (ticker: MRK) will pay $36 in cash per share for Imago (IMG), which is roughly double Imago's closing price of $17.40 a share on Friday.
"This acquisition of Imago augments our pipeline and strengthens our presence in the growing field of hematology," said Merck Chief Executive Robert Davis in a news release.
Hematology is the branch of medicine that focuses on the study of blood diseases. Imago is a clinical stage biopharmaceutical company developing new medicines for the treatment of several bone marrow diseases.
Merck's acquisition of Imago is expected to close in the first quarter of 2023.
Imago stock soared 105% to $35.65 in premarket trading on Monday. Merck stock was flat in the premarket session at $104.21 a share.
Write to Angela Palumbo at angela.palumbo@dowjones.com
(END) Dow Jones Newswires
November 21, 2022 07:29 ET (12:29 GMT)
New York Yankees and Duke Basketball
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM